Robert Hazlett
Stock Analyst at BTIG
(0.57)
# 3,938
Out of 4,883 analysts
23
Total ratings
33.33%
Success rate
-23.52%
Average return
Main Sectors:
Stocks Rated by Robert Hazlett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Maintains: Buy | $21 → $24 | $6.16 | +289.61% | 3 | Oct 18, 2024 | |
| NKTR Nektar Therapeutics | Assumes: Buy | $60 | $23.47 | +155.65% | 2 | Sep 30, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $7 → $14 | $0.54 | +2,510.48% | 2 | May 9, 2024 | |
| LYRA Lyra Therapeutics | Maintains: Buy | $1,200 → $1,000 | $9.03 | +10,974.20% | 1 | Feb 7, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $62 → $98 | $107.50 | -8.84% | 2 | Dec 23, 2022 | |
| VSTM Verastem | Maintains: Buy | $96 → $60 | $4.69 | +1,179.32% | 3 | Oct 5, 2022 | |
| CMPS COMPASS Pathways | Initiates: Buy | $63 | $3.31 | +1,803.32% | 1 | May 27, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | $29 | $6.29 | +361.05% | 4 | Feb 2, 2021 | |
| RDHL RedHill Biopharma | Initiates: Buy | $26,000 | $2.06 | +1,262,035.92% | 1 | Sep 11, 2020 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $26 → $6 | $3.63 | +65.29% | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $15.06 | +19.52% | 2 | Aug 31, 2017 | |
Aura Biosciences
Oct 18, 2024
Maintains: Buy
Price Target: $21 → $24
Current: $6.16
Upside: +289.61%
Nektar Therapeutics
Sep 30, 2024
Assumes: Buy
Price Target: $60
Current: $23.47
Upside: +155.65%
Rani Therapeutics Holdings
May 9, 2024
Maintains: Buy
Price Target: $7 → $14
Current: $0.54
Upside: +2,510.48%
Lyra Therapeutics
Feb 7, 2023
Maintains: Buy
Price Target: $1,200 → $1,000
Current: $9.03
Upside: +10,974.20%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62 → $98
Current: $107.50
Upside: -8.84%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96 → $60
Current: $4.69
Upside: +1,179.32%
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: $63
Current: $3.31
Upside: +1,803.32%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: $29
Current: $6.29
Upside: +361.05%
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: $26,000
Current: $2.06
Upside: +1,262,035.92%
Akebia Therapeutics
Sep 4, 2020
Maintains: Buy
Price Target: $26 → $6
Current: $3.63
Upside: +65.29%
Aug 31, 2017
Initiates: Buy
Price Target: $18
Current: $15.06
Upside: +19.52%